Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Follow-on Public Offering	Asset Purchase Agreement	High Trail	July 13, 2020	August 10, 2020	Common Stock	Common Stock Follow-on Public Offering	Common Stock Asset Purchase Agreement	Common Stock High Trail	Common Stock July 13, 2020	Common Stock July 20, 2020	Common Stock September 30, 2020	Common Stock August 10, 2020	Common Stock March 12, 2020	Common Stock June 30, 2020	Additional Paid-in Capital	Additional Paid-in Capital Follow-on Public Offering	Additional Paid-in Capital Asset Purchase Agreement	Additional Paid-in Capital High Trail	Additional Paid-in Capital July 13, 2020	Additional Paid-in Capital August 10, 2020	Accumulated Deficit	Accumulated Other Comprehensive Income/(Loss)
Beginning balance at Dec. 31, 2019	$ 10,727						$ 2										$ 140,477						$ (129,809)	$ 57
Beginning balance, shares at Dec. 31, 2019							17,736,649
Net loss	(18,772)																						(18,772)
Issuance of common stock		$ 23,416																$ 23,416
Issuance of common stock, shares								3,860,710
Reclassification of warrants to equity	204																204
Issuance of restricted common stock					$ 49	$ 760															$ 49	$ 760
Issuance of restricted common stock, shares							134,364				10,000	95,500	22,700	90,000	439,145	134,364
Forfeiture of restricted common stock, shares							(134,366)								(371,329)	(134,366)
Shares of restricted common stock retired in connection with vesting	(139)																(139)
Shares of restricted common stock retired in connection with vesting, shares							41,299
Stock-based compensation expense	17,192																17,192
Exercise of stock options	12																12
Exercise of stock options, shares							2,870
Other comprehensive loss	(28)																							(28)
Ending balance at Sep. 30, 2020	33,421						$ 2										181,971						(148,581)	29
Ending balance, shares at Sep. 30, 2020							21,844,944
Beginning balance at Jun. 30, 2020	5,222						$ 2										152,948						(147,776)	48
Beginning balance, shares at Jun. 30, 2020							17,763,164
Net loss	(805)																						(805)
Issuance of restricted stock awards, shares												95,500	22,700	90,000
Issuance of common stock		$ 23,416																$ 23,416
Issuance of common stock, shares								3,860,710
Reclassification of warrants to equity	204																204
Issuance of restricted common stock					$ 49	$ 760															$ 49	$ 760
Issuance of restricted common stock, shares											10,000
Stock-based compensation expense	4,582																4,582
Exercise of stock options	12																12
Exercise of stock options, shares							2,870
Other comprehensive loss	(19)																							(19)
Ending balance at Sep. 30, 2020	33,421						$ 2										181,971						(148,581)	29
Ending balance, shares at Sep. 30, 2020							21,844,944
Beginning balance at Dec. 31, 2020	23,382						$ 3										216,305						(192,935)	9
Beginning balance, shares at Dec. 31, 2020							27,074,791
Net loss	(229,415)																						(229,415)
Issuance of common stock upon exercise of stock option grants	8,749																8,749
Issuance of common stock upon exercise of stock option grants, shares							1,011,422
Issuance of common stock related to exercise of warrants	40,284																40,284
Issuance of common stock related to exercise of warrants, shares							2,926,508
Issuance of common stock in connection with acquisition of Healing Solution assets	39,454																39,454
Issuance of common stock in connection with acquisition of Healing Solutions assets, shares							1,387,759
Issuance of restricted stock awards	4,412																4,412
Issuance of restricted stock awards, shares							254,104
Issuance of warrants to High Trail	39,016																39,016
Issuance of common stock	36,735		$ 11,075	$ 129,620						$ 2							36,735		$ 11,075	$ 129,618
Issuance of common stock, shares							2,666,667		704,548	12,284,161
Reclassification of warrants to equity	97,088																97,088
Reclassification of warrants to liability	(21,260)																(21,260)
Issuance of restricted common stock, shares							2,020,697
Forfeiture of restricted common stock, shares							(280,997)
Fair value of warrant modification on extinguishment	17,399																17,399
Stock-based compensation expense	$ 16,421																16,421
Exercise of stock options, shares	1,011,422
Other comprehensive loss	$ (305)																							(305)
Ending balance at Sep. 30, 2021	212,655						$ 5										635,296						(422,350)	(296)
Ending balance, shares at Sep. 30, 2021							50,049,660
Beginning balance at Jun. 30, 2021	175,777						$ 3										487,605						(311,794)	(37)
Beginning balance, shares at Jun. 30, 2021							35,734,767
Net loss	(110,556)																						(110,556)
Issuance of common stock related to exercise of warrants, shares							1,879,368
Issuance of common stock				$ 125,564						$ 2										$ 125,562
Issuance of common stock, shares										12,154,161
Reclassification of warrants to equity	17,065																17,065
Reclassification of warrants to liability	(21,260)																(21,260)
Issuance of restricted common stock, shares							125,055
Forfeiture of restricted common stock, shares							(22,026)
Fair value of warrant modification on extinguishment	17,399																17,399
Issuance of RSU issued to consultant	1,043																1,043
Issuance of RSU issued to consultant, shares							145,408
Stock-based compensation expense	7,882																7,882
Exercise of stock options, shares							32,927
Other comprehensive loss	(259)																							(259)
Ending balance at Sep. 30, 2021	$ 212,655						$ 5										$ 635,296						$ (422,350)	$ (296)
Ending balance, shares at Sep. 30, 2021							50,049,660